Cardinal Health (CAH) has been frequently discussed on the stock market, standing strong amidst occasional dips and losses in the market. The company's board has approved an increase to its quarterly dividend, attracting the attention and investment from wealth management entities, such as Kingsview. A deal to purchase Specialty Networks is likely to boost the company's market portfolio. However, the company has experienced incidents such as a product recall for kits containing Shenli's syringes and the loss of contracts from OptumRX. Despite challenges, Cardinal Health continued to reaffirm its Fiscal 2024 non-GAAP EPS guidance and long-term targets. Experts suggest that the stock may be a strong value investment for the long-term, especially considering its history of exceeding analyst EPS forecasts. Yet, volatile changes, including missed expectations for Q3 2024 and reduced profit forecasts, bring some uncertainty. Cardinal Health continues to receive new price targets from various financial entities and the company is making strategic moves such as streamlining operations. It remains a favorite amongst institutional investors, contributing to the company's resilience. Regulatory hurdles, such as the FDA's warning for adulterated and misbranded medical devices, also factor into the company's overall market posture.
Cardinal Health CAH News Analytics from Tue, 15 Aug 2023 07:00:00 GMT to Sun, 21 Jul 2024 12:33:57 GMT -
Rating 6
- Innovation 3
- Information 8
- Rumor -1
